Healthcare Business

clinical trials

Lipocine Crashes After Receiving CRL From the FDA

Lipocine Inc. (NASDAQ: LPCN) is watching its shares get cut in half in Wednesday’s session after receiving a letter from the U.S. Food and Drug Administration (FDA). The company announced ...
Read Full Story »
Female patient on gurney

Is Galena Dead in the Water After This Failed Trial?

Galena Biopharma, Inc. (NASDAQ: GALE) is absolutely crashing on Wednesday after the company released further information regarding its Breast Cancer clinical trial. The company announced the recommendation from the Independent ...
Read Full Story »
Medicine pills

Eli Lilly Rises on Positive FDA Committee Vote

Eli Lilly and Co. (NYSE: LLY) is watching its shares make a decent gain on Wednesday following a U.S. Food and Drug Administration (FDA) vote. The FDA Advisory Committee voted ...
Read Full Story »
doctor

Why Tesaro Is Skyrocketing

Tesaro, Inc. (NASDAQ: TSRO) is watching its shares make a significant gain on Wednesday after the company released positive late-stage trial results. The company announced that its Phase 3 NOVA ...
Read Full Story »
automatic inspection machine

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health ...
Read Full Story »
IPO

inVentiv Updates IPO Filing

inVentiv Group Holdings filed an amended Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were mentioned in this filing, ...
Read Full Story »
biotech word cloud

Why Regulus Is Tanking

Regulus Therapeutics Inc. (NASDAQ: RGLS) saw its shares cut in half early Tuesday morning following news of a clinical hold from the U.S. Food and Drug Administration (FDA). The company ...
Read Full Story »
puzzle

DENTSPLY Slides on Acquisition News

DENTSPLY International Inc. (NASDAQ: XRAY) saw its shares pull back slightly in Monday’s session following news of an acquisition. The company announced a definitive agreement to acquire all of the ...
Read Full Story »
health square image copy

Medtronic Moves to Acquire Heartware

Heartware International (NASDAQ: HTWR) is watching its shares absolutely skyrocket in Monday’s session despite the huge market downturn from the Brexit. This surge is the result of Medtronic PLC (NYSE: ...
Read Full Story »
health care

Medpace Files for IPO

Medpace Holdings, Inc. filed a Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). There were no pricing details mentioned in the filing but the ...
Read Full Story »
Prescription Drugs, Pills

Short Sellers Increase Bets Against Major Pharmaceutical Stocks

The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After ...
Read Full Story »
white pills

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked valuations ...
Read Full Story »
graph

A Biotech and a Medical Device Stock, Each With Massive Upside Potential

Long-time aggressive investors know that biotechnology stocks can offer huge upside and also can get absolutely hammered, and in some cases even go out of business. Needless to say the ...
Read Full Story »
clinical trials

Why Nymox Pharmaceutical Took Off

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) shares made solid headway in Wednesday’s session on positive results from a cancer trial. The company announced results from its seven-year prospective placebo controlled double-blind ...
Read Full Story »